• Peer Reviewed Publications of Novaliq

Lei Tian et al.: JAMA Ophthalmol. Published online March 16, 2023. doi:10.1001/jamaophthalmol.2023.0270

Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial

Tauber et al.: Ophthalmology 2022 December, published Ahead of Print

NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study

Jacobi et al.; Journal of Ocular Pharmacology and Therapeutics 2022 May, Publish Ahead of Print

A Water-Free Omega-3 Fatty Acid Eye Drop Formulation for the Treatment of Evaporative Dry Eye Disease: A Prospective, Multicenter Noninterventional Study

Sheppard et al.; Cornea 2021; Jan; Publish Ahead of Print.

Results of the Randomized Phase 2B/3 ESSENCE study with CyclASol 0.1% for treatment of dry eye disease

Tauber et al.; Cornea 2020 Dec 22; Publish Ahead of Print.

Randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease

Hyeck-Soo Son et al.; Journal of Refractive Surgery 2020; 36: 474-480

Semi-fluorinated Alkane Eye Drops Reduce Signs and Symptoms of Evaporative Dry Eye Disease After Cataract Surgery

Doreen Schmidl et al.; Journal Ocular Pharmacology and Therapeutics 2020; 36: 154-161

Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial

Agarwal et al.; Eur. Pharm. Biopharm 2019; 142:83-91

Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections

Agarwal et al; OcularSurface 2019

Preclinical Studies Evaluating the Effect of Semifluorinated Alkanes on Ocular Surface and Tear Fluid Dynamics

Eberwein et al.; Ophthalmic Res 2019

Semifluorinated Alkane Eye Drops in Chronic Ocular Graft-versus-Host Disease: A Prospective, Multicenter, Noninterventional Study

Wirta et al.; Ophthalmology 2019

A Clinical Phase 2 Study to Assess Efficacy, Safety and Tolerability of CyclASol® for Treatment of Dry Eye Disease (DED)

Agarwal et al.; IntJPharm 2018; 538:119-129

Semifluorinated alkane based systems for enhanced corneal penetratoin of poorly soluble drugs

De Majumdar et al.; CurrMolMed 2017; 17:211-220

A Low concentration of Tacrolismus /Semifluorinate Alkane (SFA) Eyedrop suppresses intraocular inflammation in experimental models of uveitis

Gehlsen et al.; GraefesArchClinExpOphal 2017; 255:767-775

A Semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic options for topical treatment of dry eye

Runnsjoe et al.; JChemThermodynam 2017; 105:352-361

Semifluorinated Alkanes and Alkanes-A Phase Study of the Perfluorohexyloctane – Tetradecane System

Steven et al.; JOculPharmacolTher 2017; 33:678-685

Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease

Steven et al.; KlinMonatsblAugenheilkd 2017; 234:662-669

Influence of Aging on Severity and Anti-Inflammatory Treatment of Experimental Dry Eye Disease

Steven et al; JOculPharmacolTher 2015; 31:498-503

Semifluorinated alkane eye drops for treatment of dry eye disease